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Abstract
Epilepsy is a chronic disorder characterized by a spontaneous tendency to recurrent
seizures  which  affects  patients’  cognitive,  behavioral,  psychological,  and  social
functioning. Epileptic patients face various problems that result in a lower quality of
life. Seizure frequency, drug side effects, psychological comorbidity, and stigma are
the major factors affecting the quality of lives of patients with epilepsy. Depression,
anxiety, psychosis, and cognitive impairment are some of the comorbid psychiatric
problems accompanying the clinical picture in epilepsy. Also the role of antiepileptic
drugs (AEDs) in psychopathology of epilepsy should not be underestimated. One of
the most important reasons why health-related quality of life (HRQOL) has become
important  for  epileptic  patients  is  related  with  well-known  characteristics  of  this
disorder. Its chronic nature, presence of unexpected, intractable and frequent seizures,
and stigma are some of these characteristics among others. With the review of the
current literature, it can be concluded that there is still a need for further scientific
research to find out more clear relation between epilepsy, comorbidities, and HRQOL.
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1. Introduction
Epilepsy is a chronic disorder characterized by recurrent seizures which impairs patient’s
quality of life through cognitive, behavioral, psychological, and social functioning [1]. It has
been reported that the total lifetime risk for epilepsy and for any unprovoked seizure are 3.1
and 4.1%, respectively in industrialized countries.  The estimation of annual incidence of
epilepsy is reported as high as 43 cases per 100,000 of the population in so-called developed
countries, and is almost double this figure in the developing world [2]. Another estimation
points out that there are 50 million people who have epilepsy in the world [3, 4]. It was
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suggested that more than 80% of people with epilepsy live in developing countries, where the
condition remains largely untreated [5, 6].
The science of health-related quality of life (HRQOL) measurements rapidly evolved during
the 1980s and 1990s within general health and in all medicine disciplines [7]. HRQOL has
become so important for patients with epilepsy (PWE) because of well-known characteristics
of this disorder. Among these characteristics, chronic nature, unexpectability, intractable and/
or frequent seizures, stigma, and side effects of the antiepileptic drugs are acknowledged. Also,
neurobiological, cognitive, psychological, and social consequences of epilepsy are very
important [8].
Patients with epilepsy (PWE) encounter various problems due to this disorder which conduce
a lower quality of life (QOL). Seizure frequency, side effects of the antiepileptic drugs,
psychological problems, and stigma are the major factors determining severity of the disease
and these factors may cause an important impact on life quality of PWE. Therefore, identifying
the factors which mostly affect are important for improving epileptic patients’ quality of lives
[9].
2. Psychiatric comorbidities
2.1. Depression
Psychiatric disorders are frequent in epilepsy and they have a marked effect in QOL, morbidity,
and mortality. Mood and anxiety disorders are the most frequent problems [10]. Depression
is the most frequent psychiatric comorbidity in epilepsy, affecting one of every three patients
with epilepsy in clinical studies [11] and lifetime prevalence rates of depression range between
30 and 35% in patients with epilepsy [10].
The International League Against Epilepsy (ILAE) has recognized the importance of comor-
bidities in the management of PWE. But, these comorbidities are usually ignored, unless they
lead to a major disability. This may be related to several factors, such as patients not giving
enough information about their psychiatric state or neurologists may not be specifically trained
for these comorbidities [12]. In a recent study reported by Kanner et al., it was demonstrated
that comorbid psychiatric problems affect the quality of life, so patients with subsyndromic
depressive episodes (SSDEs), major depressive episodes (MDEs), anxiety disorders, and mixed
MDEs (or SSDEs) with anxiety disorders have a significantly worse QOL than asymptomatic
patients [13]. Authors also demonstrated that occurrence of mixed disorders resulted with
unfavorable HRQOL than the occurrence of anxiety disorders alone. Another important
finding of this study was that the comorbid occurrence of depression and anxiety disorders
accompanied to epilepsy cause to important clinical results beyond their impact on HRQOL
which include:
1. An increased suicidal risk.
2. A worse course and poorer response to treatment of a depressive disorder.
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3. An increased risk of MDE recurrence; types of anxiety increased the probability of a new
depressive episode.
4. Pharmacoresistant temporal lobe epilepsy patients encountered unsatisfied results
including increased risk of failure to achieve seizure-free state after anterotemporal
lobectomy [13].
Literature survey reveals enough evidence regarding the negative impact of mood disorders
and anxiety symptoms on the quality of life of PWEs [14–20]. Symptoms of depression and
anxiety are independently associated with reduced HRQOL; psychiatric comorbidity explains
more variance in HRQOL than the combined groups of clinical seizure or demographic
variables [18]. A study with a large sample included 435 PWEs aiming to investigate the relative
impact of mood and anxiety symptoms as well as social- and seizure-related variables on
HRQOL [21]; the presence of depressive symptoms was the strongest predictor of the compo-
site and subscales of the Quality of Life in Epilepsy instrument used (QOLIE-31). In other
studies conducted on patients with pharmacoresistant temporal lobe epilepsy (TLE), symp-
toms of depression were found to be the strongest independent predictors of poor QOL but
(unexpectedly) not the seizure frequency or severity [14, 15, 17].
Kim et al. studied impact of depression and anxiety on adverse event profiles in Korean people
with epilepsy. Consecutively, 453 patients who took antiepileptic drugs for at least 1 year
completed self-reported questionnaires. They used Liverpool adverse events profile (LAEP),
Beck Depression Inventory (BDI), and Beck Anxiety Inventory (BAI). In this study, it was
reported that BAI, BDI scores, and the duration of antiepileptic drug treatment were significant
predictors [22].
Another important point is the women with epilepsy of childbearing age. Increased risk of
depression is a considerable problem for these patients. Lack of occupation, the presence of an
underlying disabling condition (with treatment), and the severity of epilepsy are the significant
properties accompanied to depression. Compared with the general population depressed
women with epilepsy display greater impairment of HRQOL with epilepsy also images the
physical, social, and emotional aspects of the disease [23].
Depressive disorders are associated with a worse response of seizures to antiepileptic drug
treatment [24]. Hitiris et al. [25] retrospectively searched 780 patients with new onset epilepsy.
Epileptic patients with a history of depression had two times more risk in developing refractory
epilepsy.
Endocrine, neurotransmitter, and immunologic disturbances were found to be related with
depression in patients with epilepsy. Especially, serotonin, glutamate, and GABA have an
important role in epileptic seizures. Fluoxetine, a selective serotonin reuptake inhibitor (SSRI),
has been shown to be effective in seizure prevention in a focal epilepsy model in rats [26].
Mazarati et al. studied an animal model of status epilepticus demonstrated abnormal 5-HT
secretion in the raphe-hippocampal serotonergic pathway, lower serotonin concentrations in
the hippocampus, and decreased serotonin release from the hippocampus following raphe
stimulation [27]. Also, fluoxetine administration reversed the cortical hyperexcitability
following status epilepticus. In animal models of depression, dysfunction of glutamate
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transporter proteins was shown, causing neuronal hyperexcitability and neuronal death [28].
In humans with depression, reduced expression of several glutamate transporter proteins was
found in the frontal cortex and striatum in postmortem brain tissue that resulted in elevated
synaptic glutamate concentrations [29]. By depression decreased cerebrospinal fluid concen-
tration of GABA [30] and intracortical GABA signal on MR spectroscopy (MRS) [21, 28, 31–
34] arises as a result of decreased GABAergic activity. For example, Rajkowska et al. [35]
determined a significant decrease in GABAergic interneurons in the dorsolateral prefrontal
cortex of the brains of the major depressive disorder patients (MDD) in a postmortem study
which included 14 MDD patients (nine of whom died because of suicide) and nine controls
[36]. Studies designed with transcranial magnetic stimulation (TMS), as a treatment modality
for resistant MDD, also display decreased GABAergic activity in patients with depression [24].
2.2. Anxiety
Clinical studies found that 11–25% of PWE suffered from anxiety, which are higher proportions
than healthy people [37]. These rates of depression and anxiety were close to that of drug-
refractory epilepsy in a long-term population-based study [38]. The prevalence of depression
or anxiety is higher in refractory epilepsy, and especially temporal lobe epilepsy (TLE), than
in the general population of PWE [39–41]. The amygdala is important for the fear sensation.
The avoidance behavior associated with fear is related to the output of the amygdala to the
peri-aqueductal gray matter. Symptoms of anxiety disorders image the activation of the fear
circuit involving structures of the hippocampus which is related with re-experiencing fear [42,
43]. Both in anxiety and epilepsy neurons discharging excitatory currents are associated with
similar mechanisms [44]. Therefore, the amygdala and hippocampus play a critical pathophy-
siological role in both anxiety and epilepsy. The orbitofrontal cortex, insula, and cingulate
gyrus are also essential in the central mediation of anxiety [45]. Inhibition of γ-aminobutyric
acid (GABA)is an important factor in the pathogenesis of anxiety [44]. The GABAA receptor
has an important role in controlling fear. Drugs affecting on GABAA receptors (like benzodia-
zepines and barbiturates) may increase the seizure threshold and also control anxiety symp-
toms by reducing neuronal excitability [46].
Tellez-Zentano et al. studied anxiety disorders in PWE; they found that people without
epilepsy reported a lifetime incidence of 11.2% for any anxiety disorder compared with 22.8%
in the group with epilepsy [10]. Rai et al. reported increased prevalence of depressive and
anxiety disorders in people with epilepsy [47, 48].
We may think that the prevalence of anxiety disorders should be higher in refractory patients
than in well-controlled patients. Brandt and Mula displayed a prevalence of 19.6% in patients
with refractory epilepsy which is not different than the ratios reported in general epilepsy
population [47]. Another important point stated was that the people with shorter epilepsy
duration and younger age were more likely to have an anxiety disorder. This could show that
the PWE can learn how to cope with the disease as getting older or with increasing duration
of the disease. Also, it has been shown that patients in younger age and shorter duration of
epilepsy are more likely to have anxiety disorders. This may be explained by patients acquiring
coping strategies as years go by Brandt and Mula [47].
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Depression and anxiety increase suicide risk, suicidal ideation, and stigmatization in PWE [37,
39]. Recent studies performed with newly diagnosed epileptic patients, identified depression,
and anxiety as risk factors of drug-refractory epilepsy [13, 25]. These risk factors have also been
associated with worse outcomes of epileptic surgery [49, 50]. In addition, depression and
anxiety have been associated with increased adverse events in response to antiepileptic drugs
(AEDs)in PWE [51]. Ultimately, the psychiatric and clinical effects of depression and anxiety
can impair the quality of life (QOL)of PWE. Therefore, early detection and management of
depression and anxiety are critical for the management of PWE.
2.3. Psychosis
There is a higher incidence of psychosis (9%) in PWE, when compared to the general popula-
tion (1%) [52]. Psychoses in epilepsy have a complex psychopathology that is similar to the
positive symptoms of schizophrenia and usually without negative symptoms [53]. Psychoses
with seizure disorders can be classified as ictal, postictal, and interictal, depending on the onset
of symptoms. Postictal psychosis most commonly appears within a week of the last seizure,
whereas psychosis in forced normalization continues to manifest after normalization and with
a clear state of consciousness [54]. Forced normalization can be defined by the emergence of
psychosis after the control of seizures. The mechanism is unknown, but it can occur whether
convulsions are controlled by medication, surgery, or neurostimulation [55]. Hilger et al.
retrospectively analyzed 1434 patients with epilepsy, evaluated with prolonged EEG moni-
toring in order to estimate the prevalence of postictal psychosis (PP) and interictal psychosis
(IP) [56]. They found that the overall prevalence of psychosis was 5.9%; prevalence of PP; and
IP was 3.7 and 2.2%, respectively. They showed that the 97.6% of the patients with psychosis
had localization-related epilepsy. Prevalence of psychosis was highest (9.3%) in patients with
temporal lobe epilepsy [56].
2.4. Cognitive impairment
Cognitive impairment is a very important problem for PWE and their families. Memory
impairment in epilepsy has been shown in neuropsychological studies and temporal lobe
epilepsy (TLE) is an important risk factor. Brain training exercises in the form of activities such
as reading, doing crosswords, and sudoku have been shown to improve memory function.
Thompson et al. studied patients with temporal lobe epilepsy who had memory impairments.
They showed that the traditional memory rehabilitation techniques can help to reduce the
burden of memory impairment in temporal lobe epilepsy [57, 58].
Regarding the psychiatric comorbidities of epilepsy, Kanner highlighted some important
points. First, he stated that the psychiatric disorders and epilepsy had a bidirectional relation-
ship. The PWE have an increased risk of developing psychiatric comorbidities, but also patients
with a primary psychiatric disorder have a greater risk of developing epilepsy. Second, he
reported that the PWE with psychiatric comorbidities are less likely to become seizure-free
with antiepileptic drugs (AEDs) and with epilepsy surgery. In addition, they are more likely
to develop adverse events to AEDs. Finally, Kanner pointed out the importance of psychiatric
evaluation of the patients with epilepsy especially who are being considered for surgery.
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Because after epilepsy surgery, presurgical comorbid disorders may remit, recur, or be
exacerbated [59].
2.5. Stigma
Stigma is associated with feared or perceived discrimination and an important psychosocial
burden in people with epilepsy. Stigma among people with epilepsy brings out impairment
in quality of life. Also, stigma is associated with aggravation of psychosocial burden like
anxiety and depression for people with epilepsy [60]. Generally, prevention of seizures is not
adequate in order to relieve the burden of epilepsy, also attenuating of perception of stigma
matters for quality of life of individual with epilepsy [61]. Beside impact of stigma on quality
of life of individual with epilepsy is frequently underestimated whereas stigma affects quality
of life more than frequency of seizure and adverse effects of antiepileptic drugs.
Fisher demonstrated psychosocial symptoms like depression were quite important as initial
reaction to the diagnosis of epilepsy and perceived stigma was associated with psychosocial
symptoms [62]. A study which was intended to obtain certain demographic, clinical, and
psychosocial traits associated with perceived stigma indicated that; being single, having poor
quality of life, having difficulty in understanding the written information, and use of behav-
ioral disengagement as a coping mechanism were enhancing factors for perceived stigma [63].
Previous studies demonstrated that low socioeconomic status compared with high socioeco-
nomic status worsens the perception of stigma among PWE [61, 64]. Baker et al. published the
largest population-based study to evaluate the stigma of epilepsy in 15 European countries
[65]. Stigma data were collected from over 5000 PWE. Perception of stigma was correlated with
anxiety, long-term health problems, injuries, and adverse effect of antiepileptic drugs [65].
Another study performed which the epilepsy-related stigma percentages were obtained from
the previous largest population-based study. Results of the study suggested overall quality of
health system, the health expenditure per capita, and the perceived quality of life have little
effect on perceived stigma among individuals with epilepsy. Mentioned trail indicated the role
of the public health system invests on awareness programs to increase public knowledge and
reduce stigma [60]. Increasing the level of contact between PWE and people without epilepsy
may lead changing negative public attitudes [66]. A trial aimed to investigate the relation
between the level of knowledge about epilepsy and perception of stigma in adolescents and
their mothers was performed. This trial demonstrated that the level of knowledge about
epilepsy among adolescents with epilepsy was significantly related to their perception of
stigma. As a result, knowledge of epilepsy can minimize the impact of perceived stigma,
depressive feelings, and anxiety. This trial indicated also that correlation between the level of
the maternal concealment behavior and adolescent with epilepsy’s perception of stigma was
more significant than maternal knowledge of epilepsy or maternal perception of stigma [67].
Stigma can be categorized into enacted stigma and perceived stigma [63]. Actual disapproba-
tion and discrimination determined against individual with epilepsy is accepted as enacted
stigma. However, perceived stigma is characterized as fear of encountering enacted stigma,
feeling guilty, and shame about epilepsy. Epilepsy is not the only highly stigmatized illness
but one of the most important of them like tuberculosis, leprosy, or HIV/AIDS [61].
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In conclusion, epilepsy is a disease with many complications which lowers quality of life of
PWE. Stigma, seizure frequency, drugs’ adverse reactions, and neuropsychiatric issues are the
major factors which are associated with the quality of lives of PWE.
2.6. Self-esteem
Self-esteem has been shown as the most important part of the ego and a major factor effecting
psychosocial well-being [68]. The most important determinants of self-esteem are what we
think of ourselves, how we assess ourselves when compared to others [68]. Literature analysis
shows different results in the correlation between epilepsy and self-esteem [69–70]. Gauffin et
al. studied self-esteem in young PWE and compared it with the earlier results [71]. They found
that there was a decline in both sense of coherence and self-esteem overtime in young adults
with epilepsy. On the other hand, Lee et al. reported that epilepsy in general has little impact
on overall self-esteem in adolescents [71].
3. Antiepileptic drugs and suicidality
The pathogenesis of AED induced depressive symptoms is probably multifactorial. In which
some of the factors are associated with the drug and other factors may be related to the patient.
GABAergic properties, rapid titration of the drug, interaction with folate metabolism may be
the drug-related factors. Whereas, poorly controlled seizures, structural abnormalities in the
limbic system like small hippocampal volumes may be the patient-related factors [72].
May be the result of effects on the function of two types of receptor GABAergic and antiglu-
tamatergic receptors are considered to be the two main receptors responsible from the
psychotropic effects of AEDs but there may also be other possible mechanisms. Presumably,
other neurochemical pathways especially a serotonergic mechanism should be considered in
psychotropic effects of AEDs [73].
People with epilepsy seemed to have an increased risk for suicide. The risk increases with a
history of a psychiatric illness. The AEDs may increase the risk of suicide in PWE, but it is not
certain. Some AEDs shown to have negative effects on mood. Especially, barbiturates, viga-
batrin, tiagabine, and topiramate were associated with depressive symptoms. In 2008, the Food
and Drug Administration (FDA) drew attention on an increased risk of suicidality in people
taking AEDs [74] and pharmaceutical companies had been asked to submit data from placebo-
controlled trials of AEDs. Suicide-related adverse events occurring during double-blind
treatment with an AED (concerning 11 AEDs) were searched. In this study, nearly 28,000 people
taking AEDs and more than 16,000 people taking placebo were analyzed. In this analysis, the
odds ratios for suicidality were increased for topiramate, but neither barbiturates nor vigaba-
trin were included in the analysis, and there were few suicidality events reported in the
tiagabine trials. Carbamazepine, lamotrigine, and valproate are used as mood stabilizers. In
the FDA analysis, carbamazepine and valproate were shown to have a nonsignificant protec-
tive effect against suicidality, whereas odds ratios of lamotrigine were significantly increased.
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Further clinical prospective studies are needed to evaluate the relation between AEDs and
suicidality because FDA analysis may have methodological concerns [72, 74].
Mood disorders, family history of a psychiatric illness, and risk of suicide must be carefully
monitored in PWE. Psychiatry consultation must be organized for patients with such symp-
toms and it is very important to choose the AEDs according to both seizure type and the risk
of possible drug induced depressive symptoms [72].
4. Quality of life in PWE
Previous researches regarding quality of life (QOL) in epilepsy showed many different results
[75, 76]. Although most studies highlighted the negative effects of epilepsy on patients’ quality
of lives, there are still some other reports which showed minor or no effect [75, 76]. Some
authors suggested that the impact of epilepsy might be minimal if the disease is stabile [75,
76]. On the other hand, epileptic patients living in Europe and North America were reported
to have important impairment in HRQOL [77, 78]. The different results reported may be
associated with the methodological and/or cultural factors. However, it can be easily noticed
that especially in studies with larger samples, HRQOL is decreased in PWE [79, 80].
Baker et al. reported that epilepsy has the potential to negatively affect different aspects of
quality of life [79]. They collected data from 3889 PWE from 10 different countries. In this
multicenter study, it was shown that nervousness, headaches, and tiredness were the most
frequent factors affecting the daily activities.
Short Form-36 (SF-36) was used in Baker et al.’s study and patients scored significantly lower
in domains such as physical and social functioning, energy, and vitality [76]. In another
multicenter study conducted by Baker et al., data from more than 5000 patients were analyzed
and reported that epilepsy had a negative effect on patients’ social and psychological well-
being [80].
Kutlu et al. investigated the HRQOL, anxiety, and depression states of patients with epilepsy
(PWE) [81]. The SF-36 scores were significantly lower in all subscales in PWE compared with
the control group. Total scores for Beck Depression Inventory (BDI) were significantly higher
in epilepsy patients. Hamilton anxiety scale was also significantly increased in PWE. It was
concluded that epilepsy significantly effects with QOL of patients. In the patient group
relationship between the seizure frequency and vitality was found to be statistically significant
[81]. Birbeck et al. in their study evaluating ability of HRQOL measures to detect change
overtime in people with epilepsy, suggested that SF-36 yielded responsiveness indices
comparable to those of the epilepsy targeted measures [82].
Recently, Chen et al. studied factors affecting QOL in 260 PWE in Taiwan in a cross-sectional,
correlational study. They used the Quality of Life in Epilepsy-31 (QOLIE-31) questionnaire for
evaluating HRQOL [9]. In this study, scores for the QOLIE-31 were correlated with the
demographic characteristics, sleep quality, symptoms of anxiety and depression, epilepsy-
specific variables such as, seizure frequency; types, number, and frequency of AEDs; and
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adverse events of AED and social support. They reported that seven factors were predictive
for quality of life: anxiety, depression, adverse events of AEDs, social support, seizure
frequency of at least once in 3 months, household income of male gender. Another recent study
was conducted by Mutluay et al., which they investigated the HRQOL in 124 PWE in Turkey
[83]. This study measured the QOL in epilepsy and determined associated demographic and
clinical factors by means of the Short Form-36 health survey. They found that patients with
epilepsy do not perceive impaired physical health status. However, their mental health appears
vulnerable, especially in women. In this study, the major burden was in the mental health
category. They also reported that a positive treatment response is an important determinant
of the HRQOL in PWE. Temporal lobe epilepsy (TLE) is the most common type of medically
intractable epilepsy and is accepted as a prototype for a surgically remediable epilepsy when
hippocampal sclerosis is the pathological substrate [84]. A reduction in seizure frequency and
an improvement in the HRQOL are expected for patients with intractable epilepsy after
epilepsy surgery [85]. Several studies indicate that complete seizure freedom is a strongly
associated with psychosocial adjustment [86]. However, others show a poor correlation with
postoperative seizure freedom. After surgery even if the seizures are completely lost, patients
may still suffer from comorbidities such as depression, anxiety, and stigma. This can be
explained by the “burden of normality” concept [84]. Patients’ status changes from chronically
ill to cured state in which the patient has to face the responsibilities of a normal life like finding
a job and learn to continue and adjust life without the “advantages” of a chronic illness.
Aydemir et al. studied 20 patients with intractable temporal lobe epilepsy who were waiting
for surgery and 21 patients who had surgery. They used SF-36, Beck Depression Inventory,
State Trait Anxiety Inventory, stigma and impact of epilepsy inventories, and a form asking
their own perspectives about epilepsy and surgery. They found that QOL of patients after
surgery was found to be better than before surgery. They also reported that seizure frequency,
comorbidity, and AEDs affected HRQOL negatively. Impact of epilepsy levels was found to be
higher among the preoperative patients [84]. A very important study was conducted by Taft
et al. [87]. In this prospective study, HRQOL, mood, and patient satisfaction in epilepsy surgery
candidates before and 2 years after epilepsy surgery was studied. They used Short Form Health
Survey (SF-36), the Hospital Anxiety and Depression scale (HAD) at baseline and after 2-year
follow-ups and also operated patients answered patient satisfaction questions. In patients who
were seizure-free after epilepsy surgery HRQOL improved and anxiety decreased. Operated
patients found surgery beneficial. But a very important point noticed in this study was that
only about half of the seizure-free patients showed HRQOL improvements, in which that
seizure freedom does not always improve patients’ quality of lives.
5. Conclusion
Psychologically, PWE may have feelings of worthlessness, fear, stigma, anger, and hopeless-
ness, and may exhibit passive behavior [88]. Stigmatization leads to discrimination, and PWE
have been the target of prejudicial behavior in many aspects of life, over many centuries and
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in many cultures [89]. These factors decrease their psychosocial function, self-efficacy, and
quality of life [90, 91] and even increase the suicide rate [90–92].
Recognition of the past and current comorbid psychiatric disorders needs to be incorporated
into the evaluation of every PWE, including those with a newly diagnosed seizure disorder.
Future research will need to determine whether an early remission of psychiatric disorders
reverses the worse course of the seizure disorder. Finally, presurgical psychiatric evaluations
must be conducted in all patients undergoing a presurgical evaluation.
Epilepsy, with its rich clinical features, is particularly important for HRQOL research. Epileptic
patients may experience various problems which will result in a lower quality of life. Seizure
frequency, side effects of the antiepileptic drugs, psychological comorbidity, and stigma are
important factors associated with the severity of the disease and these factors may cause an
important impact on life quality of epileptic patients. Stemming from a thorough review of the
current literature, we can conclude that there is still a need for further scientific research with
further validated instruments to find out more clear relation between epilepsy and HRQOL.
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